BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34504204)

  • 21. Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma
    Shan NL; Minden A; Furmanski P; Bak MJ; Cai L; Wernyj R; Sargsyan D; Cheng D; Wu R; Kuo HD; Li SN; Fang M; Maehr H; Kong AN; Suh N
    Cancer Prev Res (Phila); 2020 Aug; 13(8):673-686. PubMed ID: 32467291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune characterization of breast cancer metastases: prognostic implications.
    Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V
    Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.
    Miligy I; Mohan P; Gaber A; Aleskandarany MA; Nolan CC; Diez-Rodriguez M; Mukherjee A; Chapman C; Ellis IO; Green AR; Rakha EA
    Histopathology; 2017 Aug; 71(2):258-268. PubMed ID: 28326600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome.
    Park YH; Lal S; Lee JE; Choi YL; Wen J; Ram S; Ding Y; Lee SH; Powell E; Lee SK; Yu JH; Ching KA; Nam JY; Kim SW; Nam SJ; Kim JY; Cho SY; Park S; Kim J; Hwang S; Kim YJ; Bonato V; Fernandez D; Deng S; Wang S; Shin H; Kang ES; Park WY; Rejto PA; Bienkowska J; Kan Z
    Nat Commun; 2020 Dec; 11(1):6175. PubMed ID: 33268821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer.
    Lee S; Stewart S; Nagtegaal I; Luo J; Wu Y; Colditz G; Medina D; Allred DC
    Cancer Res; 2012 Sep; 72(17):4574-86. PubMed ID: 22751464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent.
    Agahozo MC; Westenend PJ; van Bockstal MR; Hansum T; Giang J; Matlung SE; van Deurzen CHM
    Mod Pathol; 2020 Sep; 33(9):1773-1782. PubMed ID: 32341499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.
    Abba MC; Gong T; Lu Y; Lee J; Zhong Y; Lacunza E; Butti M; Takata Y; Gaddis S; Shen J; Estecio MR; Sahin AA; Aldaz CM
    Cancer Res; 2015 Sep; 75(18):3980-90. PubMed ID: 26249178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer.
    Han SH; Kim M; Chung YR; Woo JW; Choi HY; Park SY
    Sci Rep; 2022 Nov; 12(1):20367. PubMed ID: 36437379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
    Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
    Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
    Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
    Campbell MJ; Baehner F; O'Meara T; Ojukwu E; Han B; Mukhtar R; Tandon V; Endicott M; Zhu Z; Wong J; Krings G; Au A; Gray JW; Esserman L
    Breast Cancer Res Treat; 2017 Jan; 161(1):17-28. PubMed ID: 27785654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
    Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
    Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nek2A contributes to tumorigenic growth and possibly functions as potential therapeutic target for human breast cancer.
    Wang S; Li W; Liu N; Zhang F; Liu H; Liu F; Liu J; Zhang T; Niu Y
    J Cell Biochem; 2012 Jun; 113(6):1904-14. PubMed ID: 22234886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.
    Toss MS; Miligy I; Al-Kawaz A; Alsleem M; Khout H; Rida PC; Aneja R; Green AR; Ellis IO; Rakha EA
    Mod Pathol; 2018 Aug; 31(8):1226-1236. PubMed ID: 29559742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations of B7-H3 and B7-H4 Expression in Ductal Carcinoma In Situ of the Breast With Clinicopathologic Features and T-Cell Infiltration.
    Kim NI; Park MH; Lee JS
    Appl Immunohistochem Mol Morphol; 2020; 28(10):767-775. PubMed ID: 31714284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.
    Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T
    Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma.
    Tsutsumi S; Saeki H; Nakashima Y; Ito S; Oki E; Morita M; Oda Y; Okano S; Maehara Y
    Cancer Sci; 2017 Jun; 108(6):1119-1127. PubMed ID: 28294486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TBX3 promotes progression of pre-invasive breast cancer cells by inducing EMT and directly up-regulating SLUG.
    Krstic M; Kolendowski B; Cecchini MJ; Postenka CO; Hassan HM; Andrews J; MacMillan CD; Williams KC; Leong HS; Brackstone M; Torchia J; Chambers AF; Tuck AB
    J Pathol; 2019 Jun; 248(2):191-203. PubMed ID: 30697731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes.
    Kim A; Heo SH; Kim YA; Gong G; Jin Lee H
    Am J Clin Pathol; 2016 Jul; 146(1):137-44. PubMed ID: 27402610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.